drugset
drugset / Trial / NCT02737046

Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma

NCT02737046 ↗

Phase 2 Completed 15 enrolled University of Miami
NaSingle-groupOpen-labelTreatment

Summary

The investigators propose to use Belinostat in combination with AZT as consolidation therapy for the treatment of ATLL.

Timeline

Start
2016-12-12
Primary completion
2024-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Belinostat Small molecule 750 mg/m2 Intravenous
Subject Belinostat Small molecule 1000 mg/m2 Intravenous
Subject Zidovudine Small molecule 300 mg Oral
Background Cyclophosphamide Other / unclassified 375 mg/m2 Intravenous
Background Peginterferon alfa-2b Protein / enzyme biologic 1.5 ug/kg Subcutaneous
Background interferon alfa-2b Protein / enzyme biologic 5e+06 iu Subcutaneous

Indications

adult T-cell leukemia/lymphoma